CCS LABS LTD

Executive Summary

CCS LABS LTD, a recently incorporated micro-entity engaged in scientific R&D, shows a concerning negative net asset position driven by considerable long-term liabilities despite positive short-term liquidity. While regulatory compliance is maintained and liquidity appears manageable, the lack of employees and operational history pose risks to sustainability. Further scrutiny of creditor terms and business viability is recommended to assess financial stability.

CCS LABS LTD - Analysis Report

Company Number: 14958172

Analysis Date: 2025-07-29 15:04 UTC

1. Risk Rating: HIGH
   The company shows a negative net asset position (£-10,995) due to significant long-term creditors (£50,000) exceeding total assets, indicating potential solvency issues despite positive net current assets. The micro-entity status with zero employees and limited financial history increases uncertainty about operational sustainability.

2. Key Concerns:

• Negative net assets caused by creditors due after more than one year (£50,000) exceeding total assets, signaling solvency risk.
• No employees and limited operating history (incorporated June 2023) raise questions about business viability and revenue generation.
• Sole director and 100% shareholder control concentrate decision-making and risk, with no apparent independent oversight.

3. Positive Indicators:

• Current assets exceed current liabilities by £39,005, suggesting short-term liquidity is sufficient to meet immediate obligations.
• Timely filing of accounts and confirmation statements with no overdue returns reflects compliance with regulatory requirements.
• Business classified under R&D in natural sciences and engineering (SIC 72190), an area with potential for growth and innovation.

4. Due Diligence Notes:

• Investigate nature and terms of the £50,000 long-term creditors to understand repayment obligations and their impact on solvency.
• Review business model, revenue streams, and plans for hiring or operational scaling given zero employees reported.
• Assess background and track record of sole director and shareholder for governance and management capability.
• Confirm whether any additional funding or capital injections are planned or secured to improve equity position.